Afficher la notice abrégée

Tips and Tricks and Clinical Outcome of Cryopreserved Human Amniotic Membrane Application for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Pilot Study

dc.rights.licenseopenen_US
dc.contributor.authorODET, Stephane
dc.contributor.authorMEYER, Christophe
dc.contributor.authorGAUDET, Camille
dc.contributor.authorWEBER, Elise
dc.contributor.authorQUENOT, Julie
dc.contributor.authorDERRUAU, Stephane
dc.contributor.authorLAURENCE, Sebastien
dc.contributor.authorBOMPY, Lisa
dc.contributor.authorGIRODON, Marine
dc.contributor.authorCHATELAIN, Brice
dc.contributor.authorMAUPRIVEZ, Cedric
dc.contributor.authorBRENET, Esteban
dc.contributor.authorKERDJOUDJ, Halima
dc.contributor.authorZWETYENGA, Narcisse
dc.contributor.authorMARCHETTI, Philippe
dc.contributor.authorHATZFELD, Anne-Sophie
dc.contributor.authorTOUBEAU, David
dc.contributor.authorPOUTHIER, Fabienne
dc.contributor.authorLAFARGE, Xavier
dc.contributor.authorREDL, Heinz
hal.structure.identifierBioingénierie tissulaire [BIOTIS]
dc.contributor.authorFENELON, Mathilde
hal.structure.identifierBioingénierie tissulaire [BIOTIS]
dc.contributor.authorFRICAIN, Jean-Christophe
dc.contributor.authorDI PIETRO, Roberta
dc.contributor.authorLEDOUBLE, Charlotte
dc.contributor.authorGUALDI, Thomas
dc.contributor.authorPARMENTIER, Anne-Laure
dc.contributor.authorLOUVRIER, Aurelien
dc.contributor.authorGINDRAUX, Florelle
dc.date.accessioned2023-03-16T15:10:35Z
dc.date.available2023-03-16T15:10:35Z
dc.date.issued2022
dc.identifier.issn2296-4185en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172336
dc.description.abstractEnMedication-related osteonecrosis of the jaw (MRONJ) is a complication of certain pharmacological treatments such as bisphosphonates, denosumab, and angiogenesis inhibitors. There are currently no guidelines on its management, particularly in advanced stages. The human amniotic membrane (hAM) has low immunogenicity and exerts anti-inflammatory, antifibrotic, antimicrobial, antiviral, and analgesic effects. It is a source of stem cells and growth factors promoting tissue regeneration. hAM acts as an anatomical barrier with suitable mechanical properties (permeability, stability, elasticity, flexibility, and resorbability) to prevent the proliferation of fibrous tissue and promote early neovascularization at the surgical site. In oral surgery, hAM stimulates healing and facilitates the proliferation and differentiation of epithelial cells in the oral mucosa and therefore its regeneration. We proposed using cryopreserved hAM to eight patients suffering from cancer (11 lesions) with stage 2–3 MRONJ on a compassionate use basis. A collagen sponge was added in some cases to facilitate hAM grafting. One or three hAMs were applied and one patient had a reapplication. Three patients had complete closure of the surgical site with proper epithelialization at 2 weeks, and two of them maintained it until the last follow-up. At 1 week after surgery, three patients had partial wound dehiscence with partial healing 3 months later and two patients had complete wound dehiscence. hAM reapplication led to complete healing. All patients remained asymptomatic with excellent immediate significant pain relief, no infections, and a truly positive impact on the patients’ quality of life. No adverse events occurred. At 6 months of follow-up, 80% of lesions had complete or partial wound healing (30 and 50%, respectively), while 62.5% of patients were in stage 3. Radiological evaluations found that 85.7% of patients had stable bone lesions (n = 5) or new bone formation (n = 1). One patient had a worsening MRONJ but remained asymptomatic. One patient did not attend his follow-up radiological examination. For the first time, this prospective pilot study extensively illustrates both the handling and surgical application of hAM in MRONJ, its possible association with a collagen sponge scaffold, its outcome at the site, the application of multiple hAM patches at the same time, and its reapplication.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enhuman amniotic membrane
dc.subject.enosteonecrosis
dc.subject.enoral mucosa
dc.subject.enallograft
dc.subject.enbisphosphonates
dc.subject.endenosumab
dc.subject.enantiangiogenic drugs
dc.title.enTips and Tricks and Clinical Outcome of Cryopreserved Human Amniotic Membrane Application for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Pilot Study
dc.title.alternativeFront. Bioeng. Biotechnol.en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fbioe.2022.936074en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
bordeaux.journalFrontiers in Bioengineering and Biotechnologyen_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesBioingénierie Tissulaire (BioTis) - U1026en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCHU de Bordeauxen_US
bordeaux.institutionInstitut Bergoniéen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Bioengineering%20and%20Biotechnology&rft.date=2022&rft.volume=10&rft.eissn=2296-4185&rft.issn=2296-4185&rft.au=ODET,%20Stephane&MEYER,%20Christophe&GAUDET,%20Camille&WEBER,%20Elise&QUENOT,%20Julie&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BIOTIS_FrontBioengBiotechnol_2 ...
Taille:
2.841Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée